CIBC Bancorp USA Inc. bought a brand new stake in Eli Lilly and Firm (NYSE:LLY – Free Report) in the course of the third quarter, in accordance with the corporate in its most up-to-date submitting with the Securities & Alternate Fee. The fund bought 110,064 shares of the corporate’s inventory, valued at roughly $83,979,000.
Quite a few different hedge funds have additionally added to or diminished their stakes within the inventory. Brighton Jones LLC boosted its stake in shares of Eli Lilly and Firm by 22.0% in the course of the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the corporate’s inventory valued at $7,409,000 after buying a further 1,730 shares within the final quarter. Revolve Wealth Companions LLC raised its stake in Eli Lilly and Firm by 2.8% within the fourth quarter. Revolve Wealth Companions LLC now owns 1,471 shares of the corporate’s inventory value $1,136,000 after shopping for a further 40 shares within the final quarter. Schnieders Capital Administration LLC. raised its stake in Eli Lilly and Firm by 16.7% within the second quarter. Schnieders Capital Administration LLC. now owns 7,993 shares of the corporate’s inventory value $6,231,000 after shopping for a further 1,141 shares within the final quarter. United Advisor Group LLC lifted its holdings in Eli Lilly and Firm by 47.9% within the second quarter. United Advisor Group LLC now owns 806 shares of the corporate’s inventory value $628,000 after shopping for a further 261 shares in the course of the interval. Lastly, Highview Capital Administration LLC DE lifted its holdings in Eli Lilly and Firm by 1.5% within the second quarter. Highview Capital Administration LLC DE now owns 5,793 shares of the corporate’s inventory value $4,516,000 after shopping for a further 85 shares in the course of the interval. 82.53% of the inventory is owned by hedge funds and different institutional buyers.
Eli Lilly and Firm Buying and selling Down 1.4%
Eli Lilly and Firm inventory opened at $916.88 on Thursday. The corporate has a present ratio of 1.58, a fast ratio of 1.19 and a debt-to-equity ratio of 1.54. The enterprise’s fifty day easy transferring common is $1,029.72 and its two-hundred day easy transferring common is $955.25. Eli Lilly and Firm has a 12 month low of $623.78 and a 12 month excessive of $1,133.95. The corporate has a market capitalization of $866.28 billion, a price-to-earnings ratio of 39.95, a price-to-earnings-growth ratio of 1.08 and a beta of 0.40.
Eli Lilly and Firm (NYSE:LLY – Get Free Report) final launched its earnings outcomes on Wednesday, February 4th. The corporate reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Firm had a return on fairness of 102.94% and a web margin of 31.66%.The agency had income of $19.29 billion for the quarter, in comparison with analysts’ expectations of $17.85 billion. Throughout the identical interval within the prior 12 months, the agency posted $5.32 earnings per share. The corporate’s quarterly income was up 42.6% on a year-over-year foundation. Eli Lilly and Firm has set its FY 2026 steering at 33.500-35.000 EPS. As a gaggle, equities analysts predict that Eli Lilly and Firm will submit 23.48 earnings per share for the present fiscal 12 months.
Analysts Set New Worth Targets
LLY has been the subject of a lot of analysis analyst reviews. Daiwa Securities Group upped their goal value on Eli Lilly and Firm from $1,230.00 to $1,250.00 and gave the inventory a “purchase” score in a report on Wednesday, February 18th. Loop Capital set a $1,200.00 goal value on shares of Eli Lilly and Firm in a report on Tuesday, February tenth. Truist Monetary reiterated a “purchase” score on shares of Eli Lilly and Firm in a analysis word on Monday, February twenty third. Weiss Scores reissued a “purchase (b-)” score on shares of Eli Lilly and Firm in a analysis report on Monday, December twenty second. Lastly, Wolfe Analysis boosted their value goal on shares of Eli Lilly and Firm from $1,050.00 to $1,250.00 and gave the inventory an “outperform” score in a analysis word on Wednesday, December third. Two equities analysis analysts have rated the inventory with a Sturdy Purchase score, twenty-three have given a Purchase score, 4 have given a Maintain score and one has assigned a Promote score to the corporate. In line with MarketBeat.com, Eli Lilly and Firm has a median score of “Reasonable Purchase” and a median value goal of $1,221.44.
View Our Newest Inventory Evaluation on Eli Lilly and Firm
Key Eli Lilly and Firm Information
Listed below are the important thing information tales impacting Eli Lilly and Firm this week:
Constructive Sentiment: Examine finds stopping GLP‑1s raises coronary heart assault, stroke and dying danger — this helps power use of Lilly’s diabetes/weight problems medicines, which might assist long-term income and pricing resilience. Wholesome Returns: Stopping GLP-1s raises danger of coronary heart assault, stroke and dying, research says
Constructive Sentiment: Lilly is investing closely in manufacturing capability — $1.8B to replace Indianapolis operations plus plans for a $3.5B Pennsylvania plant — which helps provide readiness as demand scales and will ease future bottlenecks. Lilly spending $1.8B to replace Indianapolis manufacturing operations Eli Lilly’s highway to Pennsylvania, particulars of latest $3.5B plant, celebrated within the Lehigh Valley
Impartial Sentiment: Opinion items weigh aggressive dynamics—some bullish views argue Lilly stays a market chief and a purchase alongside friends (Roche), highlighting structural progress; these are balanced takes moderately than new information. Roche Vs. Eli Lilly: Nvidia Offers, Weight problems Battles Stoke Rivalry (I’d Purchase Each)
Impartial Sentiment: Technical/market commentary notes the inventory is oversold after the pullback and approaching potential assist ranges—this frames a “purchase‑the‑dip” debate however just isn’t a basic catalyst. Inventory Of The Day: Is The Eli Lilly Selloff Over?
Destructive Sentiment: HSBC downgraded LLY to “Cut back” (from Maintain), reducing its value goal to $850 and citing U.S. pricing stress, intensifying competitors (oral drugs, rival GLP‑1s) and what it sees as overhyped weight problems‑market assumptions—that is the first driver of the day’s share weak spot. Eli Lilly and Firm (LLY) Will get Downgraded to Cut back From Maintain by HSBC – Right here’s Why
Destructive Sentiment: A number of analyst writeups and headlines spotlight heightened rivalry (Novo Nordisk, Roche), blended FDA indicators round oral weight problems drugs and the chance that market share/pricing assumptions for tirzepatide merchandise could also be too optimistic—including to close‑time period draw back danger. ‘Run for the Hills,’ Says Analyst About Eli Lilly Inventory (LLY) Eli Lilly Falls 5% — FDA Oral Weight problems Capsule Resolution and Novo Nordisk Rivalry Weigh on Shares
About Eli Lilly and Firm
(Free Report)
Eli Lilly and Firm (NYSE: LLY) is a world pharmaceutical firm based in 1876 and headquartered in Indianapolis, Indiana. The corporate researches, develops, manufactures and commercializes a broad vary of medicines and therapies for sufferers worldwide. Eli Lilly maintains operations and business presence throughout North America, Europe, Asia and different areas, serving each developed and rising markets. The corporate has been led in recent times by President and Chief Government Officer David A.
Featured Articles
Obtain Information & Scores for Eli Lilly and Firm Every day – Enter your e-mail handle under to obtain a concise day by day abstract of the most recent information and analysts’ scores for Eli Lilly and Firm and associated firms with MarketBeat.com’s FREE day by day e-mail publication.
